
Rx Rundown: Merck KGaA, Novartis, Hims & Hers and more
Deals: Merck KGaA struck a $3.9 billion deal for SpringWorks Therapeutics. Novartis plans to acquire Regulus Therapeutics for $800 million upfront and up to $1.7 billion overall. Biohaven signed a $600 million debt and royalty agreement with Oberland …